References
- 1. Schultes RE. The appeal of peyote (Lophophora williamsii) as a medicine. Am Anthropol. 1938;4:698-715.
- 2. Scarborough J. Drugs and medicines in the roman world. Expedition. 1996:38-51.
- 3. Patrick GL. An Introduction to Medicinal Chemistry. Wyd. 5. Oxford University Press; 2013.
- 4. Zając M, Pawełczyk E, Jelińska A. Chemia lekow dla studentow farmacji i farmaceutow. Wyd. 2. UM Poznań; 2006.
- 5. Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schaefer-Korting M. Farmakologia i toksykologia. Wyd. 3. Wrocław: Elsevier; 2012.
- 6. Silverman RB. Chemia organiczna w projektowaniu lekow. Warszawa: Wydawnictwo Naukowo-Techniczne; 2004.
- 7. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702.
- 8. Matosiuk D, Fidecka S, Antkiewicz-Michaluk L, Dybala I, Koziol AE. Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. Part 3. Synthesis and pharmacological activity of 1-aryl-5,6(1H)dioxo-2,3-dihydroimidazo [1,2-a]imidazoles. Eur J Med Chem. 2002;37:845-53.
- 9. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science, 2008;322:881-8.
- 10. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov. 2009;3:58-64.
- 11. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discoveryJ Med Chem. 2000;43:527-50.
- 12. Shi Y. Orphan nuclear receptors in drug discovery. Drug Discov Today. 2012;12:440-45.
- 13. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J. 2006;8:E239-E253.
- 14. Zucker KA, Adrian TE, Zdon MJ, Ballantyne GH, Modlin IM. Asperlicin: a unique nonpeptide cholecystokinin antagonist. Surgery. 1987;102:163-70.
- 15. Fitch RW, Spande TF, Garraffo HM, Yeh HJ, Daly JW. Phantasmidine: an epibatidine congener from the Ecuadorian poison frog Epipedobates anthonyi. J Nat Prod. 2010;73:331-7.
- 16. Kostis JB. Angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J. 1988;116:1580-91.
- 17. Hollis A. Me-too drugs: is there a problem. WHO report. 2004.
- 18. Drews J. Drug discovery: a historical perspective. Science. 2000;287: 1960-64.
- 19. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AG et al. The structural basis for agonist and partial agonist action on a β 1-adrenergic receptor. Nature. 2011;469:241.
- 20. Plunkett MJ, Ellman JA. Chemia kombinatoryczna i nowe leki. Świat Nauki. 1997;6:26-31.
- 21. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014;57:4977-5010.
- 22. Polak S, Wiśniowska B. Modelowanie komputerowe w badaniach nad lekiem - projektowanie i poszukiwanie cząstki aktywnej, ocena właściwości fizykochemicznych oraz aktywności biologicznej. Farm Pol. 2009;65:214-23.
- 23. Gruca A. Bioinformatyczne bazy danych. Warszawa: Wydawnictwo Polsko-Japońskiej Akademii Technik Komputerowych; 2010.
- 24. Berlicki L, Kafarski P. Computer-aided analysis and design of phosphonic and phosphinic enzyme inhibitors as potential drugs and agrochemicals. Curr Org Chem. 2005;9:1829-50.
- 25. Vogel G. Phylogenetic analysis: getting its day in court. Science. 1997;275:1559-60.
- 26. Honek, J. Preclinical research in drug development. Medical Writing. 2017;26:5-8.
- 27. Seńczuk W. Toksykologia wspołczesna. Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 2012.
- 28. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. London: Methuen & Co. Special edition published by Universities Federation for Animal Welfare (UFAW);1992.
- 29. Schollenberger A. Zasada 3R w ochronie zwierząt wykorzystywanych do badań naukowych. Życie Weterynaryjne. 2017;92.
- 30. Rusche B. The 3Rs and animal welfare-conf lict or the way forward. Altex. 2003;20:63-76.
- 31. Dodd A, Curtis PM, Williams LC, Love DR. Zebrafish: bridging the gap between development and disease. Hum Mol Genet. 2000;9:2443-9.
- 32. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov. 2005;4:35-44.
- 33. Lieschke G, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet. 2007;8:353-67.
- 34. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496:498-503.
- 35. Pandey BU, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 2011;63:411-36.
- 36. Brodniewicz T. Badania kliniczne. Wyd 1. Warszawa. CeDeWu. 2015.
- 37. Jachowicz R. Farmacja praktyczna. Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 2007.
- 38. Mahan V. Clinical trial phases. Int J Clin Med. 2014;5:1374-83.
- 39. National Centre for the Replacement, Refinement and Reduction of Animals in Research. https://www.nc3rs.org.uk/the-3rs (stan z 01.03.2018).
- 40. Portal Farmaceutyczno-Medyczny. Patent na lek. https://www.pfm.pl/artykuly/patent-na-lek/275 (stan z 01.03.2018).